Absorption, Distribution, Metabolism, and Excretion of [¹⁴C]BS1801, a Selenium-Containing Drug Candidate, in Rats.

ABSTRACT: BS1801 is a selenium-containing drug candidate with potential for treating liver and lung fibrosis. To fully elucidate the biotransformation of BS1801 in animals and provide sufficient preclinical drug metabolism data for human mass balance study, the metabolism of BS1801 in rats was investigated. We used radiolabeling techniques to investigate the mass balance, tissue distribution, and metabolite identification of BS1801 in Sprague-Dawley/Long-Evans rats after a single oral dose of 100 mg/kg (100 μCi/kg) [¹⁴C]BS1801: 1. The mean recovery of radioactive substances in urine and feces was 93.39% within 168 h postdose, and feces were the main excretion route. 2. Additionally, less than 1.00% of the dose was recovered from either urine or bile. 3. BS1801-related components were wide

SUBMITTER: Yang C 

PROVIDER: S-EPMC10745422 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature